Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FangzhouHKSE:06086 +0.68%11 EBITDA Margin % is 0.01% as of Dec. 2025. GuruFocus rates HKSE:06086 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Fangzhou ranks worse than 74.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Fangzhou's EBITDA for the
six
months ended in Dec. 2025 was HK$0 Mil. Fangzhou's Revenue for the
six
months ended in Dec. 2025 was HK$2,245 Mil. Therefore, Fangzhou's EBITDA margin for the quarter that ended in Dec. 2025 was 0.01%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Fangzhou EBITDA Margin % Related Terms
Fangzhou EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Fangzhou's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Fangzhou's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fangzhou EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Fangzhou's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fangzhou (HKSE:06086) has a EBITDA Margin % of 0.01% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fangzhou and its competitors. According to the industry distribution chart, Fangzhou ranks #497 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 74.5%.
Is Fangzhou's EBITDA Margin % too high?
Fangzhou's current EBITDA Margin % is 0.01%. The Healthcare Providers & Services industry median EBITDA Margin % is 10.13. Fangzhou's value of 0.01% is 99.9% below this industry median. Based on the distribution chart, Fangzhou ranks #497 out of 667 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fangzhou has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Fangzhou's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Fangzhou ranks #497 out of 667 companies for EBITDA Margin %. This places Fangzhou in the lower half of its industry. The industry median EBITDA Margin % is 10.13. Fangzhou's value of 0.01% is 99.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.13, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fangzhou's current EBITDA Margin % of 0.01% is 99.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Fangzhou and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fangzhou's current EBITDA Margin % is 0.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fangzhou stock overvalued right now?
Fangzhou (HKSE:06086) has a current EBITDA Margin % of 0.01%. The current EBITDA Margin % is 0.01% and 99.9% below the Healthcare Providers & Services industry median of 10.13. Fangzhou's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Fangzhou (HKSE:06086), the current EBITDA Margin % is 0.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services, Wholesale and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
11GF Score
Get the complete analysis for HKSE:06086
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06086 has been successfully added to your 
